Archive

ECCO 2016: Specialists gathered to discuss new data and current issues and solutions in IBD. Professor David Rubin (Chicago, USA), ECCO President Professor Séverine Vermeire (Leuven, Belgium), Professor Stefan Schreiber (Kiel, Germany) and Dr Peter Irving (London, UK) took time out to discuss with IBD.Update what they are excited about what’s coming up in the near future for patients with IBD.

ECCO 2016: Mechanisms by which inflammation resolves

Silvio Danese, Humanitas Clinical and Research Hospital, Milan, Italy. Article by Maria Dalby – The current paradigm for managing inflammatory conditions is to suppress the inflammatory response by… read more.

ECCO 2016: IOIBD: Disease severity definition in IBD. Professor Laurent Peyrin-Biroulet (Nancy University Hospital, France) discusses a new disease severity score initiated by the IOIBD

ECCO 2016: Dr Charlie Lees (Edinburgh, UK), Dr Ailsa Hart and Marian O’Connor (Harrow, UK), Dr James Lindsay (London, UK) and Dr Peter Irving (London, UK) discuss the new therapeutic landscape in IBD since changes to guidance by NICE and SMC over the last year

New drugs in IBD – by Maria Dalby Tofacitinib Two randomised placebo-controlled phase 3 studies (OCTAVE Induction 1 and 2) show that tofacitinib, an oral small-molecule Janus kinase… read more.

ECCO 2016: Professor Jean-Frederic Colombel (New York, USA) and Dr James Lindsay (Barts and the London NHS Trust, UK) discuss new data from the GEMINI programme showing patient populations that do well and long term data with vedolizumab

Update from the GEMINI study programme – by Maria Dalby Jean-Frédéric Colombel, Mount Sinai Hospital, New York, USA The GEMINI study programme is a large phase-3 clinical trial… read more.

ECCO 2016: Dr Charlie Lees (Edinburgh, UK) discusses in the video and article below the factors influencing the decision to stop treatment and discussed whether it may be possible to predict relapse using currently available methods

Stopping drugs – by Maria Dalby Charles Lees (Edinburgh, UK) Medication constitutes a large part of the IBD exposome, and stopping drug treatment should be a therapeutic goal… read more.

ECCO 2016: Professor David Rubin from Chicago discusses the challenges of UC management and optimising biological therapy

Management of ulcerative colitis: putting patients at the centre – by Maria Dalby Iris Dotan (Tel Aviv Sourasky Medical Centre, Israel), Peter Irving (Guy’s and St Thomas’ NHS… read more.

ECCO 2016: Professor Séverine Vermeire (Leuven, Belgium) discusses new patient guidelines for Crohn’s disease and ulcerative colitis which were released at this year’s 11th Congress of ECCO in Amsterdam, and Helen Terry (CCUK) discusses how they might be rolled out to patients in the UK.

ECCO-EFCCA Patient Guidelines – by Maria Dalby Marco Greco, Milan, Italy; Séverine Vermeire, University Hospital of Leuven, Belgium; Salvatore Leone, Palermo, Italy; Paolo Gionchetti, University of Bologna, Italy; Martin Kojinov, Sofia, Bulgaria; Axel… read more.

ECCO 2016: Professor Laurent Peyrin-Biroulet (Nancy, France), Professor Jean-Frederic Colombel (New York, USA), Marian O’Connor (Harrow, UK) and Dr Charlie Lees (Edinburgh, UK) give their highlights of the 11th Congress of ECCO

Herceptin plus lapatinib shows “amazing” potential in breast cancer

by Bruce Sylvester: Researchers report that Herceptin (trastuzamab) plus lapatinib can shrink breast cancer tumors in less than two weeks. The findings were reported in March at the… read more.

Smoking cessation drugs do not increase serious psychiatric side effects

by Bruce Sylvester: Smoking cessation treatment with varenicline and bupropion does increase serious neuropsychiatric side effects, researchers reported in The Lancet on April 22, 2016.

Beta-blockers cut COPD exacerbations, especially in heart failure patients

by Bruce Sylvester: Treatment with cardioselective  beta-blockers appears to reduce the risk of exacerbations in chronic obstructive pulmonary disease (COPD),  and it is especially effective in preventing COPD… read more.